Neuroderm Stock Price, News & Analysis (NASDAQ:NDRM)

$38.85 -0.05 (-0.13 %)
(As of 02/21/2018 10:19 AM ET)
Previous Close$38.90
Today's Range$38.85 - $38.95
52-Week Range$15.20 - $38.95
Volume200,900 shs
Average Volume418,712 shs
Market Capitalization$1.02 billion
P/E Ratio-18.33
Dividend YieldN/A
BetaN/A

About Neuroderm (NASDAQ:NDRM)

Neuroderm logoNeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson's disease, as well as other CNS diseases. The Company's Parkinson's disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages. Its liquid LD/CD and apomorphine formulations include ND0612H, ND0612L and ND0701. It is developing ND0612H for the treatment of patients suffering from severe Parkinson's disease. It is developing ND0612L for the treatment of patients at the moderate stage of Parkinson's disease that can no longer control motor complications with oral levodopa. It has also designed ND0701, which is an apomorphine-based product. ND0701 is for patients suffering from Parkinson's disease, may be used mostly by patients suffering from high motor fluctuations and not responding well to LD/CD.

Receive NDRM News and Ratings via Email

Sign-up to receive the latest news and ratings for NDRM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:NDRM
CUSIPN/A
Phone+972-8-9462729

Debt

Debt-to-Equity RatioN/A
Current Ratio17.69%
Quick Ratio17.69%

Price-To-Earnings

Trailing P/E Ratio-18.3254716981132
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($2.12)
Net IncomeN/A
Net MarginsN/A
Return on Equity-44.69%
Return on Assets-42.41%

Miscellaneous

Employees55
Outstanding Shares26,350,000

Neuroderm (NASDAQ:NDRM) Frequently Asked Questions

What is Neuroderm's stock symbol?

Neuroderm trades on the NASDAQ under the ticker symbol "NDRM."

How were Neuroderm's earnings last quarter?

Neuroderm Ltd (NASDAQ:NDRM) posted its quarterly earnings results on Thursday, May, 11th. The biotechnology company reported ($0.25) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.38) by $0.13. View Neuroderm's Earnings History.

Where is Neuroderm's stock going? Where will Neuroderm's stock price be in 2018?

8 brokers have issued twelve-month target prices for Neuroderm's stock. Their forecasts range from $39.00 to $70.00. On average, they anticipate Neuroderm's share price to reach $45.86 in the next year. View Analyst Ratings for Neuroderm.

What are Wall Street analysts saying about Neuroderm stock?

Here are some recent quotes from research analysts about Neuroderm stock:

  • 1. According to Zacks Investment Research, "Neuroderm Ltd. is a clinical-stage pharmaceutical company. It is developing next-generation treatments for central nervous system (CNS) disorders. The Company develops liquid levodopa (LD), which is a treatment for Parkinson's disease (PD). Its product pipelines includes ND0612L for moderate PD, ND0612H for severe PD, ND0680 for severe PD, ND0701 for severe PD and ND0801for Cognitive Disorders. NeuroDerm Ltd. is headquartered in Rehovot, Israel. " (10/18/2017)
  • 2. Cowen Inc analysts commented, "Neuroderm announced the preliminary Phase II results for ND0612H, and importantly, the initial feedback from our consultants has been very positive. In general, our consultants believe the efficacy looks comparable to Duodopa, but with a significantly improved use and safety profile. These data substantially de-risk the program. The current valuation is dramatically understated." (3/1/2017)

Who are some of Neuroderm's key competitors?

Who are Neuroderm's key executives?

Neuroderm's management team includes the folowing people:

  • Robert Taub, Chairman of the Board
  • Oded S. Liebermann, Chief Executive Officer, Director
  • Roy Golan CPA, Chief Financial Officer
  • , Bio & Compensation - 
  • Tami Yardeni, Chief Operating Officer
  • , Bio & Compensation - 
  • Sharon Cohen-Vered Ph.D., Vice President - CMC & QA
  • Sheila Oren, Vice President - Clinical and Regulatory Affairs
  • Eran Shor, Vice President - Devices
  • , Bio & Compensation - 
  • Oron Yacoby-Zeevi, Vice President - Research & Development
  • Revital Mandil-Levin Ph.D., Head - Business Development
  • Shmuel Cabilly, Director

When did Neuroderm IPO?

(NDRM) raised $45 million in an IPO on Friday, November 14th 2014. The company issued 4,500,000 shares at a price of $10.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Oppenheimer and Roth Capital Partners were co-managers.

How do I buy Neuroderm stock?

Shares of Neuroderm can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neuroderm's stock price today?

One share of Neuroderm stock can currently be purchased for approximately $38.85.

How big of a company is Neuroderm?

Neuroderm has a market capitalization of $1.02 billion. Neuroderm employs 55 workers across the globe.

How can I contact Neuroderm?

Neuroderm's mailing address is 3 Pekeris Street, Ruhrberg Science Bldg. Rabin Science Park Bell Entrance, REHOVOT, 7670212, Israel. The biotechnology company can be reached via phone at +972-8-9462729.


MarketBeat Community Rating for Neuroderm (NDRM)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  154 (Vote Outperform)
Underperform Votes:  125 (Vote Underperform)
Total Votes:  279
MarketBeat's community ratings are surveys of what our community members think about Neuroderm and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Neuroderm (NASDAQ:NDRM) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.632.632.632.63
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $45.86$45.86$45.86$45.86
Price Target Upside: 18.80% upside18.80% upside18.80% upside18.80% upside

Neuroderm (NASDAQ:NDRM) Consensus Price Target History

Price Target History for Neuroderm (NASDAQ:NDRM)

Neuroderm (NASDAQ:NDRM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/14/2017Jefferies GroupReiterated RatingBuy$42.00LowView Rating Details
8/2/2017Roth CapitalDowngradeBuy -> Neutral$33.00 -> $39.00LowView Rating Details
7/24/2017Raymond James FinancialDowngradeOutperform -> Market Perform$39.00HighView Rating Details
7/21/2017Deutsche BankInitiated CoverageBuy -> Buy$47.00HighView Rating Details
6/14/2017CIBCUpgradeMarket Perform -> Outperform$42.00HighView Rating Details
6/14/2017OppenheimerUpgradeMarket Perform -> Outperform$42.00HighView Rating Details
3/7/2017CitigroupDowngradeOutperform -> Market PerformN/AView Rating Details
3/1/2017CowenBoost Price TargetOutperform$38.00 -> $70.00N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Neuroderm (NASDAQ:NDRM) Earnings History and Estimates Chart

Earnings by Quarter for Neuroderm (NASDAQ:NDRM)

Neuroderm (NASDAQ NDRM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017($0.47)($0.57)ViewN/AView Earnings Details
5/11/20173/31/2017($0.38)($0.25)ViewN/AView Earnings Details
3/30/201712/31/2016($0.46)($0.49)ViewN/AView Earnings Details
11/10/20169/30/2016($0.42)($0.42)ViewN/AView Earnings Details
8/25/2016Q2($0.32)($0.32)ViewListenView Earnings Details
5/26/2016Q1($0.35)($0.25)ViewListenView Earnings Details
3/31/2016Q4($0.29)($0.31)ViewListenView Earnings Details
11/11/2015Q315($0.34)($0.07)ViewListenView Earnings Details
8/6/2015Q215($0.20)($0.34)ViewListenView Earnings Details
5/27/2015Q115($0.28)($0.09)ViewListenView Earnings Details
4/2/2015Q4 2014($0.35)($2.55)ViewN/AView Earnings Details
12/18/2014Q3 2014($10.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Neuroderm (NASDAQ:NDRM) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Neuroderm (NASDAQ:NDRM)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Neuroderm (NASDAQ NDRM)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Neuroderm (NASDAQ NDRM) News Headlines

Source:
DateHeadline
Neuroderm Ltd (NDRM) Given Consensus Rating of "Buy" by BrokeragesNeuroderm Ltd (NDRM) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 8 at 8:00 AM
Neuroderm Ltd (NDRM) Receives Average Rating of "Buy" from BrokeragesNeuroderm Ltd (NDRM) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 14 at 7:44 AM
Critical Comparison: Dynavax Technologies (DVAX) and Neuroderm (NDRM)Critical Comparison: Dynavax Technologies (DVAX) and Neuroderm (NDRM)
www.americanbankingnews.com - December 6 at 3:08 PM
Analyzing Neuroderm (NDRM) and Acorda Therapeutics (ACOR)Analyzing Neuroderm (NDRM) and Acorda Therapeutics (ACOR)
www.americanbankingnews.com - November 22 at 5:26 AM
Neuroderm Ltd (NDRM) Given Average Rating of "Buy" by AnalystsNeuroderm Ltd (NDRM) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - November 19 at 8:31 AM
NeuroDerm (NDRM) and The Competition Financial ContrastNeuroDerm (NDRM) and The Competition Financial Contrast
www.americanbankingnews.com - October 30 at 9:22 PM
NeuroDerm Ltd. (NDRM) Given Consensus Recommendation of "Buy" by BrokeragesNeuroDerm Ltd. (NDRM) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 25 at 11:01 AM
Mitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDerm - GlobeNewswire (press release)Mitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDerm - GlobeNewswire (press release)
globenewswire.com - October 19 at 6:40 AM
Mitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDermMitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDerm
feeds.benzinga.com - October 18 at 4:46 AM
Zacks: Analysts Expect NeuroDerm Ltd. (NDRM) Will Post Earnings of -$0.52 Per ShareZacks: Analysts Expect NeuroDerm Ltd. (NDRM) Will Post Earnings of -$0.52 Per Share
www.americanbankingnews.com - October 15 at 12:08 AM
Zacks Investment Research Downgrades Neuroderm Ltd (NDRM) to SellZacks Investment Research Downgrades Neuroderm Ltd (NDRM) to Sell
www.americanbankingnews.com - October 8 at 11:50 PM
Critical Review: NeuroDerm (NDRM) versus Its CompetitorsCritical Review: NeuroDerm (NDRM) versus Its Competitors
www.americanbankingnews.com - October 2 at 2:22 AM
NeuroDerm Ltd. (NDRM) Given Average Recommendation of "Buy" by AnalystsNeuroDerm Ltd. (NDRM) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 30 at 10:42 AM
NeuroDerm Ltd. (NDRM) Short Interest UpdateNeuroDerm Ltd. (NDRM) Short Interest Update
www.americanbankingnews.com - September 30 at 3:26 AM
NeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma Corporation - GlobeNewswire (press release)NeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma Corporation - GlobeNewswire (press release)
globenewswire.com - September 14 at 8:11 AM
NeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma CorporationNeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma Corporation
finance.yahoo.com - September 13 at 7:01 AM
NeuroDerm Ltd. (NDRM) Given Average Rating of "Buy" by AnalystsNeuroDerm Ltd. (NDRM) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - September 5 at 10:44 AM
NeuroDerm Ltd. (NDRM) Short Interest Down 29.2% in AugustNeuroDerm Ltd. (NDRM) Short Interest Down 29.2% in August
www.americanbankingnews.com - August 29 at 1:06 AM
Stocks Under Scanner in the Biotech Space -- Merrimack Pharma, MannKind, NeuroDerm, and Celsion - PR Newswire (press release)Stocks Under Scanner in the Biotech Space -- Merrimack Pharma, MannKind, NeuroDerm, and Celsion - PR Newswire (press release)
www.prnewswire.com - August 23 at 9:05 AM
Equities Analysts Offer Predictions for NeuroDerm Ltd.s Q3 2017 Earnings (NDRM)Equities Analysts Offer Predictions for NeuroDerm Ltd.'s Q3 2017 Earnings (NDRM)
www.americanbankingnews.com - August 18 at 6:42 AM
NeuroDerm Ltd. (NASDAQ:NDRM) Rating Reiterated by Jefferies Group LLCNeuroDerm Ltd. (NASDAQ:NDRM) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - August 14 at 6:06 AM
NeuroDerm Ltd. (NASDAQ:NDRM) Receives Average Rating of "Hold" from BrokeragesNeuroDerm Ltd. (NASDAQ:NDRM) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 11 at 6:18 PM
NeuroDerm Announces Second Quarter 2017 Financial ResultsNeuroDerm Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 4 at 6:15 AM
Roth Capital Downgrades NeuroDerm Ltd. (NDRM) to NeutralRoth Capital Downgrades NeuroDerm Ltd. (NDRM) to Neutral
www.americanbankingnews.com - August 2 at 8:44 AM
NeuroDerm Announces Extraordinary General Meeting of Shareholders to Approve Acquisition by Mitsubishi Tanabe Pharma CorporationNeuroDerm Announces Extraordinary General Meeting of Shareholders to Approve Acquisition by Mitsubishi Tanabe Pharma Corporation
finance.yahoo.com - August 2 at 6:14 AM
NeuroDerm (NDRM) Catches Eye: Stock Gains 15.5% in Session - NasdaqNeuroDerm (NDRM) Catches Eye: Stock Gains 15.5% in Session - Nasdaq
www.nasdaq.com - July 27 at 4:43 AM
Featured Company News - NeuroDerm to be acquired by Mitsubishi Tanabe Pharma Corp.Featured Company News - NeuroDerm to be acquired by Mitsubishi Tanabe Pharma Corp.
finance.yahoo.com - July 27 at 4:43 AM
NeuroDerm (NDRM) Agrees to be Acquired by Japans Mitsubishi Tanabe Pharma for $1.1BNeuroDerm (NDRM) Agrees to be Acquired by Japan's Mitsubishi Tanabe Pharma for $1.1B
www.streetinsider.com - July 26 at 4:02 AM
NeuroDerm Ltd. (NDRM) Set A New High After Bought By Mitsubishi Tanabe PharmaNeuroDerm Ltd. (NDRM) Set A New High After Bought By Mitsubishi Tanabe Pharma
www.rttnews.com - July 26 at 4:02 AM
NeuroDerm (NDRM) Catches Eye: Stock Gains 15.5% in SessionNeuroDerm (NDRM) Catches Eye: Stock Gains 15.5% in Session
finance.yahoo.com - July 26 at 4:01 AM
Biotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm - TheStreet.comBiotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm - TheStreet.com
www.thestreet.com - July 25 at 6:04 AM
NeuroDerm Ltd. (NDRM) Has Leaped To A New High After Merger - NasdaqNeuroDerm Ltd. (NDRM) Has Leaped To A New High After Merger - Nasdaq
www.nasdaq.com - July 25 at 6:04 AM
Japans Nikkei inches up, caught in tight range before Fed meetingJapan's Nikkei inches up, caught in tight range before Fed meeting
finance.yahoo.com - July 25 at 6:04 AM
Aussie stocks lead a rebound for Asian markets as dollar steadiesAussie stocks lead a rebound for Asian markets as dollar steadies
finance.yahoo.com - July 25 at 6:04 AM
Nikkei edges down before Fed; Topix ends below key technical levelNikkei edges down before Fed; Topix ends below key technical level
finance.yahoo.com - July 25 at 6:04 AM
Neuroderm Ltd (NDRM) Downgraded by Raymond James Financial, Inc. to "Market Perform"Neuroderm Ltd (NDRM) Downgraded by Raymond James Financial, Inc. to "Market Perform"
www.americanbankingnews.com - July 24 at 2:52 PM
NeuroDerm To Be Bought By Japans Mitsubishi Tanabe Pharma For $1.1 Blm In CashNeuroDerm To Be Bought By Japan's Mitsubishi Tanabe Pharma For $1.1 Blm In Cash
www.rttnews.com - July 24 at 7:10 AM
NeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in CashNeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash
finance.yahoo.com - July 24 at 7:10 AM
Mitsubishi Tanabe Pharma to buy Israels Neuroderm for $1.1 blnMitsubishi Tanabe Pharma to buy Israel's Neuroderm for $1.1 bln
finance.yahoo.com - July 24 at 7:10 AM
NeuroDerm Ltd. (NASDAQ:NDRM) Coverage Initiated at Deutsche Bank AGNeuroDerm Ltd. (NASDAQ:NDRM) Coverage Initiated at Deutsche Bank AG
www.americanbankingnews.com - July 22 at 8:14 PM
Deutsche Bank Starts Neuroderm Ltd (NDRM) at Buy - StreetInsider.comDeutsche Bank Starts Neuroderm Ltd (NDRM) at Buy - StreetInsider.com
www.streetinsider.com - July 22 at 6:50 AM
Market Limps Into WeekendMarket Limps Into Weekend
finance.yahoo.com - July 22 at 6:50 AM
NeuroDerm Ltd. (NASDAQ:NDRM) Receives Average Recommendation of "Buy" from AnalystsNeuroDerm Ltd. (NASDAQ:NDRM) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 17 at 11:59 AM
NeuroDerm Ltd. (NASDAQ:NDRM) Expected to Announce Earnings of -$0.48 Per ShareNeuroDerm Ltd. (NASDAQ:NDRM) Expected to Announce Earnings of -$0.48 Per Share
www.americanbankingnews.com - July 10 at 2:15 PM
Results of NeuroDerms ND0612H Phase II Trial Presented in Oral Session at the 3rd Congress of the European Academy of NeurologyResults of NeuroDerm's ND0612H Phase II Trial Presented in Oral Session at the 3rd Congress of the European Academy of Neurology
feeds.benzinga.com - June 27 at 7:55 AM
Firm Fighting Parkinsons Hails Reviews, UpgradeFirm Fighting Parkinson's Hails Reviews, Upgrade
www.baystreet.ca - June 14 at 10:44 PM
Gainers & Losers Of June 14: OMER, EPZM, ALXN, SBBP, GBT...Gainers & Losers Of June 14: OMER, EPZM, ALXN, SBBP, GBT...
www.finanznachrichten.de - June 14 at 10:44 PM
NeuroDerm (NDRM) Design of ND0612 Phase III iNDiGO Efficacy ... - StreetInsider.comNeuroDerm (NDRM) Design of ND0612 Phase III iNDiGO Efficacy ... - StreetInsider.com
www.streetinsider.com - June 6 at 7:29 PM
NeuroDerm (NDRM) Presents ND0612H Phase II Trial Results in Late-Breaking Poster at MDS Congress - StreetInsider.comNeuroDerm (NDRM) Presents ND0612H Phase II Trial Results in Late-Breaking Poster at MDS Congress - StreetInsider.com
www.streetinsider.com - June 6 at 12:25 AM
NeuroDerm Presents ND0612H Phase II Trial Results in Late-Breaking Poster ...NeuroDerm Presents ND0612H Phase II Trial Results in Late-Breaking Poster ...
www.nasdaq.com - June 5 at 7:24 PM

SEC Filings

Neuroderm (NASDAQ:NDRM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Neuroderm (NASDAQ:NDRM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Neuroderm (NASDAQ NDRM) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.